In 2002, the Food and Drug Administration (FDA)approved atomoxetine (Strattera) for the treatment of AD/HD.
Unlike the stimulant medications, atomoxetine is not a controlled substance and can be prescribed with refills.
Atomoxetine usually takes three to four weeks of use until its effect is evident.
In January 2005 the FDA warned that evidence of atleast two cases of liver problems in an adult and teenage patient taking atomoxetine were reported.
The manufacturer of atomoxetine (Strattera) planned to notify users of the new FDA warning; however, the company, Eli Lilly & Co., believed that the risk-benefit analysis during trials of the drug was still positive.